# Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling

Article · He Y, Ma T, Xing H, Cao X, Song F, Pan Y, Ren L

- Archive id: doi:10.1016/j.ejphar.2026.179418
- Published: 2026-10-08
- Venue: European journal of pharmacology
- DOI: https://doi.org/10.1016/j.ejphar.2026.179418
- PMID: 42849688
- Citations: 0
- Source URL: https://doi.org/10.1016/j.ejphar.2026.179418
- Provenance: europepmc

## Abstract

Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear. This study investigated the protective effects of tirzepatide against high-fat, high-fructose diet (HFHFD)-induced MASLD and examined the potential involvement of macrophage Dectin-1/spleen tyrosine kinase (Syk)/nuclear factor-κB (NF-κB) signaling. After 7 weeks of HFHFD feeding to establish the MASLD model, male C57BL/6J mice received tirzepatide (10 nmol/kg, subcutaneously, every 3 days) for an additional 7 weeks. Biochemical assays, histology, hepatic RNA sequencing (RNA-seq), RT-qPCR, Western blotting, and immunofluorescence were performed. Palmitic acid (PA)-stimulated RAW264.7 cells, siRNA-mediated Dectin-1 knockdown, and a RAW264.7 cell-derived conditioned medium-based macrophage-hepatocyte indirect interaction model were used for mechanistic validation. Tirzepatide treatment improved HFHFD-induced metabolic dysfunction, liver injury, hepatic steatosis, and inflammatory responses in mice. RNA-seq revealed enrichment of C-type lectin receptor and NF-κB signaling pathways, while HFHFD-induced Clec7a upregulation was reversed by tirzepatide. Tirzepatide reduced hepatic macrophage accumulation, Dectin-1 expression, and Syk/p65 phosphorylation. In PA-stimulated RAW264.7 cells, tirzepatide suppressed pro-inflammatory cytokine expression and secretion and inhibited Dectin-1/Syk/NF-κB activation. Conditioned medium from tirzepatide-treated RAW264.7 cells attenuated lipid accumulation and abnormalities in lipid metabolism- and inflammation-related gene expression in HepG2 cells. Dectin-1 knockdown itself attenuated PA-induced inflammatory responses and was associated with a reduced additional response to tirzepatide. These findings suggest that tirzepatide alleviates HFHFD-induced MASLD, with suppression of macrophage Dectin-1/Syk/NF-κB signaling potentially contributing to these effects.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.